Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eradication of Minimal Residual Disease in Chronic Lymphocytic Leukemia with Alemtuzumab (UKCLL07)
2006-000053-22Phase 2Unknown
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoints: Primary MRD eradication and Primary safety and tolerability. Status: unknown.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2006-000053-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000053-22.